January 21, 2014

Johnson & Johnson Reports 2013 Fourth-Quarter and Full-Year Results:

2013 Fourth-Quarter Sales of $18.4 Billion increased 4.5%; EPS was $1.23
2013 Full-Year Sales of $71.3 Billion increased 6.1%; Full-Year EPS was $4.81
Excluding Special Items, 2013 Fourth-Quarter EPS was $1.24, an increase of 4.2%*
And 2013 Full-Year EPS was $5.52, an increase of 8.2%*

NEW BRUNSWICK, N.J., Jan. 21, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $18.4 billion for the fourth quarter of 2013, an increase of 4.5% as compared to the fourth quarter of 2012. Operational results increased 6.3% and the negative impact of currency was 1.8%. Domestic sales increased 7.4%, while international sales increased 2.4%, reflecting operational growth of 5.6% and a negative currency impact of 3.2%. Worldwide sales for the full-year 2013 were $71.3 billion, an increase of 6.1% versus 2012. Operational sales increased 7.7% and the negative impact of currency was 1.6%.  Domestic sales increased 7.0%, while international sales increased 5.4%, reflecting operational growth of 8.2% and a negative currency impact of 2.8%. Sales for the full year included the acquisition of Synthes, Inc. which was completed in June 2012.  Excluding this impact, net of the divestiture of the DePuy trauma business, worldwide operational sales growth was 5.2%.

Net earnings** and diluted earnings per share for the fourth quarter of 2013 were $3.5 billion and $1.23, respectively. Fourth-quarter 2013 net earnings included after-tax special items of $42 million, primarily related to an increase in the litigation accrual, an in-process research and development charge, integration and transaction costs related to the acquisition of Synthes, Inc., and program costs associated with the DePuy ASRHip, offset by a tax benefit associated with Scios, Inc. Fourth-quarter 2012 net earnings reflect after-tax special items of $0.8 billion as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items, net earnings for the quarter were $3.6 billion and diluted earnings per share were $1.24, representing increases of 5.5% and 4.2%, respectively, as compared to the same period in 2012.*

Net earnings** and diluted earnings per share for the full-year 2013 were $13.8 billion and $4.81, respectively.  Full-year net earnings reflect after-tax special items of $2.0 billion in 2013 and $3.5 billion in 2012 as detailed in the accompanying reconciliation of non-GAAP financial measures. Excluding these special items in both periods, net earnings for the full-year of 2013 were $15.9 billion and diluted earnings per share were $5.52, representing increases of 10.7% and 8.2%, respectively, as compared with the full year of 2012.*

"Johnson & Johnson delivered strong results in 2013 led by the outstanding performance in our Pharmaceutical business, the strength of key brands in our US OTC and other Consumer businesses and continued progress in integrating Synthes into our Medical Devices and Diagnostics business.  We also advanced our longer term growth drivers, bringing innovative solutions to the global healthcare market and executing with excellence", said Alex Gorsky, Chairman and Chief Executive Officer.  "I am proud of our exceptional Johnson & Johnson colleagues for their commitment to leading with purpose and advancing health and well-being for patients and consumers around the world."

The Company announced earnings guidance for full-year 2014 of $5.75 to $5.85 per share, which excludes the impact of special items.

Worldwide Consumer sales of $14.7 billion for the full-year 2013 represented an increase of 1.7% versus the prior year, consisting of an operational increase of 2.8% and a negative impact from currency of 1.1%. Domestic sales increased 2.3%; international sales increased 1.4%, which reflected an operational increase of 3.1% and a negative currency impact of 1.7%.

Positive contributors to operational results were U.S. sales of TYLENOL® and MOTRIN® analgesics; upper respiratory over-the-counter products; international sales of baby care products; sales of NEUTROGENA® and AVEENO® skin care products; and international sales of LISTERINE® oral care products .

Worldwide Pharmaceutical sales of $28.1 billion for the full-year 2013 represented an increase of 10.9% versus the prior year with an operational increase of 12.0% and a negative impact from currency of 1.1%. Domestic sales increased 12.3%; international sales increased 9.6%, which reflected an operational increase of 11.8% and a negative currency impact of 2.2%.

Primary contributors to operational sales growth were REMICADE® (infliximab) and SIMPONI® (golimumab), biologics approved for the treatment of a number of immune-mediated inflammatory diseases; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis; INVEGA® SUSTENNA®/XEPLION® (paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for the treatment of schizophrenia in adults;  PREZISTA® (darunavir), a treatment for HIV; DOXIL® (doxorubicin HCl liposome injection)/CAELYX® (pegylated liposomal doxorubicin hydrochloride), a medication to treat recurrent ovarian and other cancers; VELCADE® (bortezomib), a treatment for multiple myeloma; and sales of new products. 

The strong sales results of new products included ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; XARELTO® (rivaroxaban), an oral anticoagulant; the combined sales of COMPLERA®/EVIPLERA® (emtricitabine /rilpivirine/tenofovir disoproxil fumarate) and EDURANT® (rilpivirine) for the treatment of HIV and INVOKANA® (canagliflozin) for the treatment of adults with type 2 diabetes.

Sales results were negatively impacted by loss of exclusivity for ACIPHEX®/ PARIET® (rabeprazole), a proton pump inhibitor for gastrointestinal disorders and CONCERTA® (methylphenidate HCI) for the treatment of attention deficit hyperactivity disorder.

During the quarter, the U.S. Food and Drug Administration (FDA) granted approval of OLYSIO (simeprevir) for combination treatment of chronic hepatitis C.  The FDA also approved IMBRUVICA (ibrutinib) to treat mantle cell lymphoma for patients who received at least one prior treatment. The European Commission approved INVOKANA® (canagliflozin) for the treatment of adults with type 2 diabetes.  In addition, SIRTURO® (bedaquiline) received a positive opinion from the European Committee for Medicinal Products for use as part of combination therapy to treat adults with pulmonary multi-drug resistant tuberculosis.

A Marketing Authorization Application was submitted to the European Medicines Agency (EMA) for ibrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.  Also filed with the EMA, was a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen-Cilag International NV marketed as PREZISTA®, with cobicistat, a pharmacokinetic boosting agent, developed by Gilead Sciences, Inc. for use in combination with other HIV medicines.

Worldwide Medical Devices and Diagnostics (MD&D) sales of $28.5 billion for the full-year 2013 represented an increase of 3.9% versus the prior year with an operational increase of 6.1% and a negative impact from currency of 2.2%. Domestic sales increased 3.5%.  International sales increased 4.2%, which reflected an operational increase of 8.3% and a negative currency impact of 4.1%. Sales included the impact of the acquisition of Synthes, Inc., net of the divestiture of the DePuy trauma business. Excluding this impact, worldwide MD&D operational sales growth was 0.1%.

Primary contributors to operational growth were sales from the acquisition of Synthes, Inc. and joint reconstruction products in the Orthopaedics business; Biosense Webster's electrophysiology products in the Cardiovascular Care business; the Vision Care business; as well as biosurgicals and international sales of energy products in the Specialty Surgery business.               

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings** and diluted earnings per share, excluding special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.  A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

** Net earnings and diluted earnings per share attributable to Johnson & Johnson.

Johnson & Johnson will conduct a meeting with investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliation of non-GAAP financial measures, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development can be found on the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS

(This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson.   Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

 

Johnson & Johnson and Subsidiaries

















Supplementary Sales Data





































(Unaudited; Dollars in Millions)

FOURTH QUARTER


TWELVE MONTHS






Percent Change






Percent Change


2013


2012


Total


Operations


Currency


2013


2012


Total


Operations


Currency

Sales to customers by




















segment of business








































Consumer




















    U.S.

$   1,263


1,203


5.0

%

5.0


-


$   5,162


5,046


2.3

%

2.3


-

    International

2,490


2,449


1.7


4.1


(2.4)


9,535


9,401


1.4


3.1


(1.7)


3,753


3,652


2.8


4.4


(1.6)


14,697


14,447


1.7


2.8


(1.1)





















Pharmaceutical




















    U.S.

3,551


3,013


17.9


17.9


-


13,948


12,421


12.3


12.3


-

    International

3,745


3,512


6.6


9.0


(2.4)


14,177


12,930


9.6


11.8


(2.2)


7,296


6,525


11.8


13.1


(1.3)


28,125


25,351


10.9


12.0


(1.1)





















Med Devices & Diagnostics




















    U.S.

3,200


3,244


(1.4)


(1.4)


-


12,800


12,363


3.5


3.5


-

    International

4,106


4,137


(0.7)


3.7


(4.4)


15,690


15,063


4.2


8.3


(4.1)


7,306


7,381


(1.0)


1.5


(2.5)


28,490


27,426


3.9


6.1


(2.2)





















U.S.

8,014


7,460


7.4


7.4


-


31,910


29,830


7.0


7.0


-

International

10,341


10,098


2.4


5.6


(3.2)


39,402


37,394


5.4


8.2


(2.8)

Worldwide

$ 18,355


17,558


4.5

%

6.3


(1.8)


$ 71,312


67,224


6.1

%

7.7


(1.6)

 

Johnson & Johnson and Subsidiaries















Supplementary Sales Data




































(Unaudited; Dollars in Millions)

FOURTH QUARTER


TWELVE MONTHS






Percent Change






Percent Change


2013


2012


Total


Operations


Currency


2013


2012


Total


Operations


Currency

Sales to customers by




















geographic area








































U.S.

$   8,014


7,460


7.4

%

7.4


-


$ 31,910


29,830


7.0

%

7.0


-





















Europe

4,968


4,603


7.9


4.8


3.1


18,599


16,945


9.8


7.7


2.1

Western Hemisphere excluding U.S.

1,891


1,941


(2.6)


4.8


(7.4)


7,421


7,207


3.0


8.9


(5.9)

Asia-Pacific, Africa

3,482


3,554


(2.0)


7.0


(9.0)


13,382


13,242


1.1


8.6


(7.5)

International

10,341


10,098


2.4


5.6


(3.2)


39,402


37,394


5.4


8.2


(2.8)





















Worldwide

$ 18,355


$ 17,558


4.5

%

6.3


(1.8)


$ 71,312


$ 67,224


6.1

%

7.7


(1.6)

 

Johnson & Johnson and Subsidiaries







Condensed Consolidated Statement of Earnings 















(Unaudited; in Millions Except Per Share Figures)

FOURTH QUARTER












2013


2012


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$ 18,355


100.0


$ 17,558


100.0


4.5

Cost of products sold

5,955


32.5


6,003


34.2


(0.8)

Selling, marketing and administrative expenses

5,917


32.2


5,661


32.2


4.5

Research and development expense

2,411


13.1


2,331


13.3


3.4

In-process research and development

338


1.9


55


0.3



Interest (income) expense, net

116


0.6


89


0.5



Other (income) expense, net

868


4.7


319


1.8



Earnings before provision for taxes on income

2,750


15.0


3,100


17.7


(11.3)

Provision for/(Benefit from) taxes on income

(769)


(4.2)


533


3.1



Net earnings

3,519


19.2


2,567


14.6


37.1

Add: Net loss attributable to noncontrolling interest

-


-


-


-



Net earnings attributable to Johnson & Johnson

$   3,519


19.2


$   2,567


14.6


37.1











Net earnings per share attributable to Johnson & Johnson (Diluted)

$     1.23




$     0.91




35.2











Average shares outstanding (Diluted)

2,872.0




2,833.4















Effective tax rate

(28.0)

%



17.2

%














Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)






Earnings before provision for taxes on income

$   3,909


21.3


$   4,115


23.4


(5.0)

Net earnings attributable to Johnson & Johnson

$   3,561


19.4


$   3,376


19.2


5.5

Net earnings per share attributable to Johnson & Johnson (Diluted)

$     1.24




$     1.19




4.2

Effective tax rate

8.9

%



18.0

%














(1) See Reconciliation of Non-GAAP Financial Measures.








 

Johnson & Johnson and Subsidiaries








Condensed Consolidated Statement of Earnings 

















(Unaudited; in Millions Except Per Share Figures)

TWELVE MONTHS












2013


2012


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$ 71,312


100.0


$ 67,224


100.0


6.1

Cost of products sold

22,342


31.3


21,658


32.2


3.2

Selling, marketing and administrative expenses

21,830


30.6


20,869


31.0


4.6

Research and development expense

8,183


11.5


7,665


11.4


6.8

In-process research and development

580


0.8


1,163


1.7



Interest (income) expense, net

408


0.6


468


0.7



Other (income) expense, net

2,498


3.5


1,626


2.5



Earnings before provision for taxes on income

15,471


21.7


13,775


20.5


12.3

Provision for taxes on income

1,640


2.3


3,261


4.9


(49.7)

Net earnings

13,831


19.4


10,514


15.6


31.5

Add: Net loss attributable to noncontrolling interest

-


-


339


0.5



Net earnings attributable to Johnson & Johnson

$ 13,831


19.4


$ 10,853


16.1


27.4











Net earnings per share attributable to Johnson & Johnson (Diluted)

$     4.81




$     3.86




24.6











Average shares outstanding (Diluted)

2,877.0




2,812.6















Effective tax rate

10.6

%



23.7

%














Adjusted earnings before provision for taxes and net earnings attributable to Johnson & Johnson (1)






Earnings before provision for taxes on income

$ 19,169


26.9


$ 18,214


27.1


5.2

Net earnings attributable to Johnson & Johnson

$ 15,876


22.3


$ 14,345


21.3


10.7

Net earnings per share attributable to Johnson & Johnson (Diluted)

$     5.52




$     5.10




8.2

Effective tax rate

17.2

%



21.2

%














(1) See Reconciliation of Non-GAAP Financial Measures.










 

Johnson & Johnson and Subsidiaries










Reconciliation of Non-GAAP Financial Measures
























Fourth Quarter


% Incr. /



Twelve Months 


% Incr. /


(Dollars in Millions Except Per Share Data)

2013


2012


(Decr.)



2013


2012


(Decr.)
















Earnings before provision for taxes on income - as reported

$ 2,750


3,100


(11.3)

%


$ 15,471


13,775


12.3

%















Litigation expenses

506


471





2,282


1,229


















In-process research and development

338


55





580


1,163


















Synthes integration/transaction costs and currency related

181


406





683


1,028


















DePuy ASR™ Hip program

134


83





251


110


















Intangible asset write-downs 

-


-





-


939


















Other

-


-





(98)


(30)


















Earnings before provision for taxes on income - as adjusted

$ 3,909


4,115


(5.0)

%


$ 19,169


18,214


5.2

%















Net Earnings attributable to Johnson & Johnson - as reported

$ 3,519


2,567


37.1

%


$ 13,831


10,853


27.4

%















Litigation expenses

227


371





1,646


1,052


















In-process research and development

294


59





462


743

(1)

















Synthes integration/transaction costs and currency related

110


306





483


899


















DePuy ASR™ Hip program

118


73





240


97


















Intangible asset write-downs

-


-





-


717


















Scios Tax Benefit

(707)


-





(707)


-


















Other

-


-





(79)


(16)


















Net Earnings attributable to Johnson & Johnson - as adjusted 

$ 3,561


3,376


5.5

%


$ 15,876


14,345


10.7

%















Diluted Net Earnings per share attributable to Johnson & Johnson - as reported

$   1.23


0.91


35.2

%


$     4.81


3.86


24.6

%















Litigation expenses

0.08


0.13





0.57


0.37


















In-process research and development

0.10


0.02





0.16


0.27


















Synthes integration/transaction costs and currency related

0.04


0.11





0.17


0.32


















DePuy ASR™ Hip program

0.04


0.02





0.08


0.03


















Intangible asset write-downs

-


-





-


0.26


















Scios Tax Benefit

(0.25)


-





(0.25)


-


















Other

-


-





(0.02)


(0.01)


















Diluted Net Earnings per share attributable to Johnson & Johnson - as adjusted 

$   1.24


1.19


4.2

%


$     5.52


5.10


8.2

%





























(1) Amount includes third quarter in-process research and development charge of $679M related to bapineuzumab IV offset by $339M reported as net loss attributable to noncontrolling interest















The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.

 


REPORTED SALES vs. PRIOR PERIOD ($MM)




FOURTH QUARTER


TWELVE MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2) (4)
















BABY CARE
















US


$          105


103

1.9%

1.9%

-



$          413


412

0.2%

0.2%

-

Intl


480


469

2.3%

7.1%

-4.8%



1,882


1,842

2.2%

5.7%

-3.5%

WW


585


572

2.3%

6.2%

-3.9%



2,295


2,254

1.8%

4.7%

-2.9%

ORAL CARE
















US


153


165

-7.3%

-7.3%

-



602


641

-6.1%

-6.1%

-

Intl


265


251

5.6%

8.6%

-3.0%



1,020


983

3.8%

5.9%

-2.1%

WW


418


416

0.5%

2.3%

-1.8%



1,622


1,624

-0.1%

1.1%

-1.2%

OTC (3)
















US


332


273

21.6%

21.6%

-



1,286


1,074

19.7%

19.7%

-

Intl


747


743

0.5%

1.1%

-0.6%



2,742


2,692

1.9%

2.3%

-0.4%

WW


1,079


1,016

6.2%

6.6%

-0.4%



4,028


3,766

7.0%

7.3%

-0.3%

SKIN CARE
















US


432


385

12.2%

12.2%

-



1,752


1,699

3.1%

3.1%

-

Intl


538


509

5.7%

7.4%

-1.7%



1,952


1,919

1.7%

2.6%

-0.9%

WW


970


894

8.5%

9.5%

-1.0%



3,704


3,618

2.4%

2.9%

-0.5%

WOMEN'S HEALTH
















US


38


82

-53.7%

-53.7%

-



280


336

-16.7%

-16.7%

-

Intl


310


325

-4.6%

-0.8%

-3.8%



1,288


1,289

-0.1%

2.9%

-3.0%

WW


348


407

-14.5%

-11.5%

-3.0%



1,568


1,625

-3.5%

-1.1%

-2.4%

WOUND CARE/OTHER (3)
















US


203


195

4.1%

4.1%

-



829


884

-6.2%

-6.2%

-

Intl


150


152

-1.3%

0.6%

-1.9%



651


676

-3.7%

-2.8%

-0.9%

WW


353


347

1.7%

2.6%

-0.9%



1,480


1,560

-5.1%

-4.7%

-0.4%

















TOTAL CONSUMER
















US


1,263


1,203

5.0%

5.0%

-



5,162


5,046

2.3%

2.3%

-

Intl


2,490


2,449

1.7%

4.1%

-2.4%



9,535


9,401

1.4%

3.1%

-1.7%

WW


$       3,753


3,652

2.8%

4.4%

-1.6%



$     14,697


14,447

1.7%

2.8%

-1.1%

































See footnotes at end of schedule















 


REPORTED SALES vs. PRIOR PERIOD ($MM)




FOURTH QUARTER


TWELVE MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

PHARMACEUTICAL SEGMENT (2) (4)
















IMMUNOLOGY
















US


$       1,726


1,448

19.2%

19.2%

-



$       6,591


5,972

10.4%

10.4%

-

Intl


676


528

28.0%

31.9%

-3.9%



2,599


1,902

36.6%

40.1%

-3.5%

WW


2,402


1,976

21.6%

22.6%

-1.0%



9,190


7,874

16.7%

17.5%

-0.8%

     REMICADE
















     US 


982


871

12.7%

12.7%

-



3,891


3,583

8.6%

8.6%

-

     US Exports (5)


367


347

5.8%

5.8%

-



1,339


1,470

-8.9%

-8.9%

-

     Intl


363


286

26.9%

30.7%

-3.8%



1,443


1,086

32.9%

36.2%

-3.3%

     WW


1,712


1,504

13.8%

14.5%

-0.7%



6,673


6,139

8.7%

9.3%

-0.6%

     SIMPONI
















     US


112


72

55.6%

55.6%

-



404


292

38.4%

38.4%

-

     Intl


142


109

30.3%

37.0%

-6.7%



528


315

67.6%

75.1%

-7.5%

     WW


254


181

40.3%

44.3%

-4.0%



932


607

53.5%

57.4%

-3.9%

     STELARA
















     US


265


158

67.7%

67.7%

-



957


627

52.6%

52.6%

-

     Intl


152


111

36.9%

37.8%

-0.9%



547


398

37.4%

38.3%

-0.9%

     WW


417


269

55.0%

55.4%

-0.4%



1,504


1,025

46.7%

47.0%

-0.3%

     OTHER IMMUNOLOGY
















     US


-


-

-

-

-



-


-

-

-

-

     Intl


19


22

-13.6%

-7.7%

-5.9%



81


103

-21.4%

-18.5%

-2.9%

     WW


19


22

-13.6%

-7.7%

-5.9%



81


103

-21.4%

-18.5%

-2.9%

INFECTIOUS DISEASES
















US


302


236

28.0%

28.0%

-



1,077


974

10.6%

10.6%

-

Intl


642


620

3.5%

3.0%

0.5%



2,473


2,220

11.4%

11.5%

-0.1%

WW


944


856

10.3%

9.9%

0.4%



3,550


3,194

11.1%

11.1%

0.0%

     INCIVO
















     US


-


-

-

-

-



-


-

-

-

-

     Intl


107


138

-22.5%

-23.6%

1.1%



517


443

16.7%

17.5%

-0.8%

     WW


107


138

-22.5%

-23.6%

1.1%



517


443

16.7%

17.5%

-0.8%

     INTELENCE
















     US


49


46

6.5%

6.5%

-



187


176

6.3%

6.3%

-

     Intl


46


38

21.1%

20.2%

0.9%



192


173

11.0%

10.8%

0.2%

     WW


95


84

13.1%

12.7%

0.4%



379


349

8.6%

8.5%

0.1%

     PREZISTA
















     US


229


165

38.8%

38.8%

-



807


672

20.1%

20.1%

-

     Intl


232


188

23.4%

22.8%

0.6%



866


742

16.7%

16.2%

0.5%

     WW


461


353

30.6%

30.3%

0.3%



1,673


1,414

18.3%

18.1%

0.2%

     OTHER INFECTIOUS DISEASES
















     US


24


25

-4.0%

-4.0%

-



83


126

-34.1%

-34.1%

-

     Intl


257


256

0.4%

0.4%

0.0%



898


862

4.2%

4.4%

-0.2%

     WW


281


281

0.0%

0.0%

0.0%



981


988

-0.7%

-0.5%

-0.2%

















 


REPORTED SALES vs. PRIOR PERIOD ($MM)




FOURTH QUARTER


TWELVE MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

















NEUROSCIENCE
















US


611


601

1.7%

1.7%

-



2,584


2,611

-1.0%

-1.0%

-

Intl


1,040


1,088

-4.4%

0.1%

-4.5%



4,083


4,107

-0.6%

3.4%

-4.0%

WW


1,651


1,689

-2.2%

0.7%

-2.9%



6,667


6,718

-0.8%

1.6%

-2.4%

     CONCERTA/METHYLPHENIDATE
















     US


46


116

-60.3%

-60.3%

-



308


609

-49.4%

-49.4%

-

     Intl


123


127

-3.1%

0.7%

-3.8%



474


464

2.2%

5.0%

-2.8%

     WW


169


243

-30.5%

-28.5%

-2.0%



782


1,073

-27.1%

-25.9%

-1.2%

     INVEGA
















     US


87


76

14.5%

14.5%

-



316


299

5.7%

5.7%

-

     Intl


67


71

-5.6%

0.8%

-6.4%



267


251

6.4%

12.3%

-5.9%

     WW


154


147

4.8%

7.9%

-3.1%



583


550

6.0%

8.7%

-2.7%

     INVEGA SUSTENNA/ XEPLION
















     US


188


132

42.4%

42.4%

-



690


482

43.2%

43.2%

-

     Intl


162


96

68.8%

69.4%

-0.6%



558


314

77.7%

76.8%

0.9%

     WW


350


228

53.5%

53.7%

-0.2%



1,248


796

56.8%

56.4%

0.4%

     RISPERDAL CONSTA
















     US


113


103

9.7%

9.7%

-



440


439

0.2%

0.2%

-

     Intl


208


255

-18.4%

-16.0%

-2.4%



878


986

-11.0%

-8.7%

-2.3%

     WW


321


358

-10.3%

-8.6%

-1.7%



1,318


1,425

-7.5%

-5.9%

-1.6%

     OTHER NEUROSCIENCE
















     US


177


174

1.7%

1.7%

-



830


782

6.1%

6.1%

-

     Intl


480


539

-10.9%

-4.8%

-6.1%



1,906


2,092

-8.9%

-3.3%

-5.6%

     WW


657


713

-7.9%

-3.3%

-4.6%



2,736


2,874

-4.8%

-0.7%

-4.1%

ONCOLOGY
















US


216


135

60.0%

60.0%

-



848


506

67.6%

67.6%

-

Intl


897


684

31.1%

32.9%

-1.8%



2,925


2,123

37.8%

39.7%

-1.9%

WW


1,113


819

35.9%

37.4%

-1.5%



3,773


2,629

43.5%

45.0%

-1.5%

     VELCADE
















     US


-


-

-

-

-



-


-

-

-

-

     Intl


524


502

4.4%

7.4%

-3.0%



1,660


1,500

10.7%

13.6%

-2.9%

     WW


524


502

4.4%

7.4%

-3.0%



1,660


1,500

10.7%

13.6%

-2.9%

     ZYTIGA
















     US


211


114

85.1%

85.1%

-



750


463

62.0%

62.0%

-

     Intl


284


150

89.3%

86.5%

2.8%



948


498

90.4%

88.4%

2.0%

     WW


495


264

87.5%

85.9%

1.6%



1,698


961

76.7%

75.6%

1.1%

     OTHER ONCOLOGY
















     US


5


21

-76.2%

-76.2%

-



98


43

*

*

-

     Intl


89


32

*

*

-1.8%



317


125

*

*

-2.2%

     WW


94


53

77.4%

79.1%

-1.7%



415


168

*

*

-1.7%

































































 


REPORTED SALES vs. PRIOR PERIOD ($MM)




FOURTH QUARTER


TWELVE MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

TOTAL OTHER
















US


696


593

17.4%

17.4%

-



2,848


2,358

20.8%

20.8%

-

Intl


490


592

-17.2%

-16.4%

-0.8%



2,097


2,578

-18.7%

-18.2%

-0.5%

WW


1,186


1,185

0.1%

0.5%

-0.4%



4,945


4,936

0.2%

0.5%

-0.3%

     ACIPHEX/PARIET
















     US


(24)


92

*

*

-



265


372

-28.8%

-28.8%

-

     Intl


53


94

-43.6%

-43.1%

-0.5%



205


463

-55.7%

-55.5%

-0.2%

     WW


29


186

-84.4%

-84.2%

-0.2%



470


835

-43.7%

-43.6%

-0.1%

     PROCRIT/EPREX
















     US


168


171

-1.8%

-1.8%

-



795


805

-1.2%

-1.2%

-

     Intl


139


155

-10.3%

-10.7%

0.4%



569


657

-13.4%

-14.0%

0.6%

     WW


307


326

-5.8%

-6.0%

0.2%



1,364


1,462

-6.7%

-7.0%

0.3%

     XARELTO
















     US


271


95

*

*

-



864


239

*

*

-

     Intl


-


-

-

-

-



-


-

-

-

-

     WW


271


95

*

*

-



864


239

*

*

-

     OTHER
















     US


281


235

19.6%

19.6%

-



924


942

-1.9%

-1.9%

-

     Intl


298


343

-13.1%

-11.6%

-1.5%



1,323


1,458

-9.3%

-8.2%

-1.1%

     WW


579


578

0.2%

1.1%

-0.9%



2,247


2,400

-6.4%

-5.8%

-0.6%

















TOTAL PHARMACEUTICAL
















US


3,551


3,013

17.9%

17.9%

-



13,948


12,421

12.3%

12.3%

-

Intl


3,745


3,512

6.6%

9.0%

-2.4%



14,177


12,930

9.6%

11.8%

-2.2%

WW


$       7,296


6,525

11.8%

13.1%

-1.3%



$     28,125


25,351

10.9%

12.0%

-1.1%


















See footnotes at end of schedule.

 


REPORTED SALES vs. PRIOR PERIOD ($MM)




FOURTH QUARTER


TWELVE MONTHS






% Change






% Change



2013


2012

Reported

Operational (1)

Currency



2013


2012

Reported

Operational (1)

Currency

MEDICAL DEVICES AND DIAGNOSTICS (2)
















CARDIOVASCULAR CARE
















US


$          210


186

12.9%

12.9%

-



$          808


752

7.4%

7.4%

-

Intl


324


320

1.3%

5.7%

-4.4%



1,269


1,233

2.9%

7.0%

-4.1%

WW


534


506

5.5%

8.3%

-2.8%



2,077


1,985

4.6%

7.2%

-2.6%

DIABETES CARE
















US


219


295

-25.8%

-25.8%

-



998


1,312

-23.9%

-23.9%

-

Intl


344


349

-1.4%

0.2%

-1.6%



1,311


1,304

0.5%

1.6%

-1.1%

WW


563


644

-12.6%

-11.9%

-0.7%



2,309


2,616

-11.7%

-11.2%

-0.5%

DIAGNOSTICS
















US


215


258

-16.7%

-16.7%

-



926


1,025

-9.7%

-9.7%

-

Intl


251


272

-7.7%

-2.5%

-5.2%



959


1,044

-8.1%

-3.6%

-4.5%

WW


466


530

-12.1%

-9.4%

-2.7%



1,885


2,069

-8.9%

-6.6%

-2.3%

INFECTION PREVENTION/OTHER
















US


90


86

4.7%

4.7%

-



361


399

-9.5%

-9.5%

-

Intl


156


160

-2.5%

5.2%

-7.7%



551


553

-0.4%

6.4%

-6.8%

WW


246


246

0.0%

5.0%

-5.0%



912


952

-4.2%

-0.3%

-3.9%

ORTHOPAEDICS
















US 


1,307


1,246

4.9%

4.9%

-



5,074


4,144

22.4%

22.4%

-

Intl


1,149


1,142

0.6%

3.5%

-2.9%



4,435


3,655

21.3%

24.6%

-3.3%

WW


2,456


2,388

2.8%

4.2%

-1.4%



9,509


7,799

21.9%

23.4%

-1.5%

SPECIALTY SURGERY
















US


332


326

1.8%

1.8%

-



1,303


1,297

0.5%

0.5%

-

Intl


351


329

6.7%

10.7%

-4.0%



1,289


1,229

4.9%

8.1%

-3.2%

WW


683


655

4.3%

6.3%

-2.0%



2,592


2,526

2.6%

4.2%

-1.6%

SURGICAL CARE 
















US


599


618

-3.1%

-3.1%

-



2,294


2,415

-5.0%

-5.0%

-

Intl


1,040


1,049

-0.9%

3.4%

-4.3%



3,975


4,068

-2.3%

1.3%

-3.6%

WW


1,639


1,667

-1.7%

1.0%

-2.7%



6,269


6,483

-3.3%

-1.0%

-2.3%

VISION CARE
















US


228


229

-0.4%

-0.4%

-



1,036


1,019

1.7%

1.7%

-

Intl


491


516

-4.8%

4.0%

-8.8%



1,901


1,977

-3.8%

4.3%

-8.1%

WW


719


745

-3.5%

2.6%

-6.1%



2,937


2,996

-2.0%

3.3%

-5.3%

















TOTAL MEDICAL DEVICES AND DIAGNOSTICS
















US


3,200


3,244

-1.4%

-1.4%

-



12,800


12,363

3.5%

3.5%

-

Intl


4,106


4,137

-0.7%

3.7%

-4.4%



15,690


15,063

4.2%

8.3%

-4.1%

WW


$       7,306


7,381

-1.0%

1.5%

-2.5%



$     28,490


27,426

3.9%

6.1%

-2.2%

































* Percentage greater than 100%
















(1) Operational growth excludes the effect of currency














(2) Unaudited
















(3) Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals









(4) Prior year amounts have been reclassified to conform to current year product disclosure








(5) Reported as U.S. sales
















SOURCE Johnson & Johnson

News Provided by Acquire Media


Close window | Back to top

Copyright 2014 Johnson & Johnson

This site is governed solely by applicable U.S laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy.Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson.Contact Us with any questions or search this site for more information.